|1.||Peloquin, Charles A: 6 articles (11/2009 - 08/2003)|
|2.||Tuberculosis Trials Consortium: 5 articles (06/2007 - 12/2004)|
|3.||Siegel, David: 4 articles (12/2015 - 04/2012)|
|4.||Ross, David: 4 articles (12/2015 - 04/2012)|
|5.||Burman, William: 4 articles (05/2010 - 05/2005)|
|6.||Khan, Awal: 4 articles (02/2006 - 12/2004)|
|7.||Kitson, Russell R A: 3 articles (12/2015 - 04/2013)|
|8.||Moody, Christopher J: 3 articles (12/2015 - 04/2013)|
|9.||Misra, Amit: 3 articles (04/2012 - 06/2009)|
|10.||Lindeboom, Jerome A: 3 articles (01/2011 - 04/2007)|
11/01/1994 - "KRM showing much more potent in vitro activity against the MAC organisms compared to rifabutin (RBT) and RFP, also exerted markedly greater therapeutic efficacy against the MAC infections induced in mice or rabbits in terms of reducing the incidence and the extent of gross pulmonary lesions and the bacterial loads in the lungs and spleens. "
04/01/1994 - "Clinical tests on more than 1,000 patients have shown the benefit of Ansatipine in the prophylactic treatment of MAC infections: reduction by half on the frequency of surveillance, prolongation of the delay in appearance, significant improvement in general condition and quality of life of the patients. "
11/01/1988 - "Rifabutin was moderately effective against an environmental serotype 8 strain of MAC and of significant effectiveness against low dose aerogenic infections with two strains of higher virulence. "
05/01/2010 - "Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection."
01/01/2007 - "Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for Helicobacter pylori (HP) infection, but it has not been analysed as a second-line treatment. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
12/01/1995 - "An analysis of the combined double-blind and open-label follow-up of two clinical trials of rifabutin prophylaxis for MAC supports the suggestion of the double-blind study that rifabutin improves survival of AIDS patients."
12/01/1995 - "Data from 1146 AIDS patients with CD4+ counts < or = 200 x 10(6)/l enrolled at 73 US and Canadian sites in two clinical trials of MAC prophylaxis were analyzed using Cox proportional hazards analysis with rifabutin use modeled as a time-dependent covariate, taking into account the initial randomized double-blind phase of the trials and the subsequent open-label phase of follow-up of those patients. "
12/01/1995 - "Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS."
01/01/1995 - "Clinical trials have proven the therapeutic value of rifabutin especially in AIDS patients with concomitant MAC. "
05/01/2009 - "Rifabutin corneal deposits in a patient with acquired immunodeficiency syndrome: in vivo confocal microscopy investigation."
04/01/1994 - "Rifabutin reduced the incidence of MAC bacteremia by approximately one-half and, when disseminated disease due to MAC (DMAC) did develop, reduced the frequency of associated clinical symptoms. "
08/01/1999 - "The study included two patient groups: 73 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 30 cells/microL) who were treated between February 1992 and July 1993 and who had not received rifabutin prophylaxis (Group R-), as well as 90 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 22 cells/microL) who had received rifabutin 300 mg/day as primary prophylaxis against MAC bacteremia between July 1993 and November 1995 (Group R+). "
12/01/1995 - "Rifabutin prophylaxis has been shown to significantly decrease the incidence of Mycobacterium avium complex (MAC) bacteremia in two randomized controlled clinical trials, but a survival benefit has not been observed. "
04/01/1994 - "Controlled trials of rifabutin for the prophylaxis of MAC bacteremia have been completed. "
09/16/1993 - "In the second trial, bacteremia developed in 51 of 282 patients in the placebo group (18 percent) and 24 of 274 patients in the rifabutin group (9 percent) (P = 0.002). "
12/01/2007 - "Patients were enrolled in a prospective trial of rifabutin-based tuberculosis (TB) treatment for human immunodeficiency virus related TB. "
01/01/2007 - "HIV-positive people with tuberculosis, the group most likely to benefit from the rifabutin use, are under-represented in trials to date, and further trials in this group would be useful."
12/15/2004 - "We evaluated cases of recurrent tuberculosis in two prospective clinical trials: a randomized study of two regimens for the last 4 months of treatment (n = 1,075) and a study of a twice-weekly rifabutin-containing regimen for human immunodeficiency virus-infected tuberculosis (n = 169). "
04/01/1996 - "This article reviews recent studies conducted outside the United States assessing the efficacy and safety of rifabutin in the treatment of tuberculosis (TB) in HIV-infected patients, in patients with newly diagnosed TB, and in patients with multidrug-resistant TB. "
02/01/2015 - "This work focuses on the interaction of the anti-tuberculosis (anti-TB) drug, rifabutin (RFB) with cell membrane models formed by 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). "
|5.||Crohn Disease (Crohn's Disease)
01/01/2002 - "Only 5 Crohn's disease patients (13.8%) were non-responders, noticing no marked improvement while on rifabutin and macrolide antibiotic therapy. "
06/01/2010 - "This is only the second published case of corneal deposits in conjunction with rifabutin therapy for Crohn's disease. "
06/01/2010 - "To report a case of corneal endothelial deposits associated with rifabutin therapy for Crohn's disease. "
06/01/2010 - "Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease."
01/01/2007 - "However, use of rifabutin in the management of Crohn's disease is controversial and not widely known to an ophthalmic readership. "
|4.||Blood Transfusion (Blood Transfusions)
|5.||Drug Therapy (Chemotherapy)